Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
IPO Year:
Exchange: NYSE
Website: zimmerbiomet.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/1/2024 | $140.00 → $115.00 | Overweight → Neutral | Piper Sandler |
5/30/2024 | $129.00 | Neutral | Goldman |
5/21/2024 | $150.00 | Hold → Buy | Argus |
1/4/2024 | $135.00 → $125.00 | Outperform → In-line | Evercore ISI |
10/20/2023 | $120.00 | Neutral | ROTH MKM |
8/28/2023 | $139.00 | Neutral → Buy | BTIG Research |
5/3/2023 | Underperform → Neutral | BofA Securities | |
4/11/2023 | $135.00 → $148.00 | In-line → Outperform | Evercore ISI |
3/31/2023 | $115.00 → $130.00 | Underperform → Hold | Jefferies |
3/29/2023 | $112.00 | Sell | UBS |
Truist Securities analyst Richard Newitter maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Hold and lowers the price target from $130 to $117.
Morgan Stanley analyst Cecilia Furlong maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Equal-Weight and lowers the price target from $130 to $120.
Citigroup analyst Joanne Wuensch maintains Zimmer Biomet Holdings (NYSE:ZBH) with a Neutral and lowers the price target from $134 to $120.
Evercore ISI Group analyst Vijay Kumar maintains Zimmer Biomet Holdings (NYSE:ZBH) with a In-Line and lowers the price target from $130 to $115.
Throughout the last three months, 8 analysts have evaluated Zimmer Biomet Holdings (NYSE:ZBH), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 5 1 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 1 1 2 1 0 3M Ago 0 0 2 0 0 In the assessment of 12-month price targets, analysts unveil insights for Zimmer Biomet Holdings, presenting an average target of $134.25, a high estimate of $155.00, and a low estimate of $115.00. This current averag
Piper Sandler analyst Matthew O'Brien downgrades Zimmer Biomet Holdings (NYSE:ZBH) from Overweight to Neutral and lowers the price target from $140 to $115.
Zimmer Biomet Holdings's (NYSE:ZBH) short percent of float has fallen 18.97% since its last report. The company recently reported that it has 4.58 million shares sold short, which is 2.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.35 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance to uncover new information. This index layers editorial commentary to help make sense of why these stocks should be of interest and whether investors or casual readers should watch them. Related Link: EXCLUSIVE – Top 10 Most Searched Tickers On Benzinga Pro In May: Where Do Nvidia, Tesla, GameStop, AMC Rank? Her
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
Acquisition Expands Hip Portfolio with Artificial Intelligence-Driven Surgical Guidance System WARSAW, Ind., Aug. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it signed a definitive agreement to acquire OrthoGrid Systems, Inc., (OrthoGrid) a privately-held medical technology company focused on artificial intelligence (AI)-driven surgical guidance systems for total hip replacement. The acquisition includes OrthoGrid's AI-powered, fluoroscopy-based surgical assistance platform Hip AI®, as well as two additional FDA-cleared orthopedic applications and over 40 patents.
Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basisSecond quarter diluted earnings per share were $1.18; adjusted1 diluted earnings per share were $2.01The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted1 earnings per share financial guidanceWARSAW, Ind., Aug. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2024. The Company reported second quarter net sales of $1.942 billion, an increase of 3.9% over the prior year period, and an increase of 5.6% on a constant curren
WARSAW, Ind., July 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Wednesday, August 7, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do s
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
DURHAM, N.C. and WARSAW, Ind., June 12, 2024 /PRNewswire/ -- RevelAi Health and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a multi-year co-marketing agreement to commercialize generative artificial intelligence (AI)-powered engagement solutions that advance value-based orthopedic care and health equity. During the multi-year agreement, Zimmer Biomet will commercialize RevelAi Health's patient care-management platform, care team dashboard for providers, and any future products or services. "Leveraging generative AI to s
--TMINI System Complements Company's Flagship ROSA® Robotics Portfolio Featuring Applications for Knee, Hip and Shoulder Arthroplasty-- WARSAW, Ind., June 11, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced a limited distribution agreement with THINK Surgical, Inc. regarding its wireless, handheld, TMINI Miniature Robotic System for total knee arthroplasty. The agreement will result in an exclusive offering, integrating Zimmer Biomet technology into a customized TMINI robotic solution. The TMINI system complements Zimmer Biomet's comprehensive, flagship ROSA® Robotics portfolio with a handheld robotic option that ena
WARSAW, Ind., June 4, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the Goldman Sachs 45th Annual Healthcare Conference on Tuesday, June 11, 2024, at 8:40 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference. About Zimmer Biomet Zimmer Biomet is a global medical technology lea
Presents Path for Compelling and Durable Topline Growth, Improved Operational Profitability and Increased Free Cash Flow Generation Details New Capital Allocation Priorities and Commitment to Strategic Diversification Announces Strategic Partnership with CBRE, the World's Largest Commercial Real Estate Services and Investment Firm, to Develop and Outfit Orthopedic Ambulatory Surgery Centers (ASC) in the U.S. WARSAW, Ind. and NEW YORK, May 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today hosted its 2024 Investor Day and provided an in-depth review of the Company's strategic priorities and long-range plan for growth and valu
WARSAW, Ind., May 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that it will host an Investor Day on Wednesday, May 29, 2024, at 1:00 p.m. E.T. until approximately 4:30 p.m. ET at the New York Stock Exchange in New York City. The event will feature presentations by members of the senior management team, including President and CEO Ivan Tornos and Chief Financial Officer, EVP, Finance, Operations and Supply Chain Suky Upadhyay, who will detail the Company's strategic and capital allocation prioriti
WARSAW, Ind., May 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2024. The cash dividend of $0.24 per share is payable on or about July 31, 2024 to stockholders of record as of the close of business on June 26, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seaml
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
424B5 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
FWP - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
424B5 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
10-Q - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
8-K - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Filer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
4 - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Issuer)
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the
WARSAW, Ind., Jan. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Louis A. Shapiro, formerly the President and Chief Executive Officer of the Hospital for Special Surgery (HSS), has been appointed to the Board, effective immediately. HSS has been recognized as a leading academic medical center focused on musculoskeletal health – it was ranked #1 in U.S. orthopedics hospitals for 14 years in a row by U.S. News & World Report and #1 in worldwide orthopedics hospitals by Newsweek for the past four consecutive years. Founded in 1863, HSS is the oldest orthopedics hospital in the U.S., performs more than 40,000 su
Chief Operating Officer Ivan Tornos Appointed President and CEO; Elected to the Board of Directors Chief Financial Officer Suketu (Suky) Upadhyay's Role Expands to CFO and EVP, Finance, Operations & Supply Chain Company Reaffirms Full-Year 2023 Financial Guidance WARSAW, Ind., Aug. 22, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced the appointment of Ivan Tornos as President and Chief Executive Officer (CEO) and election to the Board of Directors, effective immediately. Mr. Tornos has most recently served as Chief Operating Officer of Zimmer Biomet, a role he has held since early 2021. He takes over as President and CEO from Bryan Hanson, who has served
Expanded Role Adds Responsibility for Environmental, Social and Governance (ESG) Strategy and Office of the CEO to Portfolio WARSAW, Ind., May 26, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE:ZBH) (SIX: ZBH), a global medical technology leader, today announced the appointment of Keri P. Mattox as Chief Communications and Administration Officer, reporting to President, Chief Executive Officer and Chairman Bryan Hanson. Ms. Mattox previously served as Senior Vice President, Investor Relations and Chief Communications Officer, and now adds responsibility for building and executing a comprehensive strategy around Environmental, Social and Governance (ESG) initiatives and increasing CE
Paul Stellato Joins Zimmer Biomet as Vice President, Controller and Chief Accounting Officer WARSAW, Ind., May 16, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced the appointment of Paul Stellato as Vice President, Controller and Chief Accounting Officer. Prior to joining Zimmer Biomet, Mr. Stellato served as Vice President, Finance, Global Business Services at Xylem Inc. "With more than two decades of experience and a demonstrated track record of success in all areas of financial services, Paul will b
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
SC 13G/A - ZIMMER BIOMET HOLDINGS, INC. (0001136869) (Subject)
Piper Sandler downgraded Zimmer Biomet from Overweight to Neutral and set a new price target of $115.00 from $140.00 previously
Goldman initiated coverage of Zimmer Biomet with a rating of Neutral and set a new price target of $129.00
Argus upgraded Zimmer Biomet from Hold to Buy and set a new price target of $150.00
Evercore ISI downgraded Zimmer Biomet from Outperform to In-line and set a new price target of $125.00 from $135.00 previously
ROTH MKM initiated coverage of Zimmer Biomet with a rating of Neutral and set a new price target of $120.00
BTIG Research upgraded Zimmer Biomet from Neutral to Buy and set a new price target of $139.00
BofA Securities upgraded Zimmer Biomet from Underperform to Neutral
Evercore ISI upgraded Zimmer Biomet from In-line to Outperform and set a new price target of $148.00 from $135.00 previously
Jefferies upgraded Zimmer Biomet from Underperform to Hold and set a new price target of $130.00 from $115.00 previously
UBS initiated coverage of Zimmer Biomet with a rating of Sell and set a new price target of $112.00
Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basisSecond quarter diluted earnings per share were $1.18; adjusted1 diluted earnings per share were $2.01The Company updates 2024 reported revenue guidance due to currency expectations and reaffirms 2024 constant currency revenue growth and adjusted1 earnings per share financial guidanceWARSAW, Ind., Aug. 7, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended June 30, 2024. The Company reported second quarter net sales of $1.942 billion, an increase of 3.9% over the prior year period, and an increase of 5.6% on a constant curren
WARSAW, Ind., July 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its second quarter earnings conference call will be webcast on Wednesday, August 7, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do s
Presents Path for Compelling and Durable Topline Growth, Improved Operational Profitability and Increased Free Cash Flow Generation Details New Capital Allocation Priorities and Commitment to Strategic Diversification Announces Strategic Partnership with CBRE, the World's Largest Commercial Real Estate Services and Investment Firm, to Develop and Outfit Orthopedic Ambulatory Surgery Centers (ASC) in the U.S. WARSAW, Ind. and NEW YORK, May 29, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today hosted its 2024 Investor Day and provided an in-depth review of the Company's strategic priorities and long-range plan for growth and valu
WARSAW, Ind., May 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2024. The cash dividend of $0.24 per share is payable on or about July 31, 2024 to stockholders of record as of the close of business on June 26, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seaml
First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency1 basisFirst quarter diluted earnings per share were $0.84; adjusted1 diluted earnings per share were $1.94Company reiterates full-year 2024 financial guidanceWARSAW, Ind., May 2, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended March 31, 2024. The Company reported first quarter net sales of $1.889 billion, an increase of 3.2% over the prior year period, and an increase of 4.4% on a constant currency1 basis. Net earnings for the first quarter were $172.4 million, or $399.7 million on an adjusted1 basis.
WARSAW, Ind., April 3, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its first quarter earnings conference call will be webcast on Thursday, May 2, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do so by
WARSAW, Ind., Feb. 21, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2024. The cash dividend of $0.24 per share is payable on or about April 30, 2024 to stockholders of record as of the close of business on March 29, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We sea
Fourth quarter net sales of $1.940 billion increased 6.3% and 6.1% on a constant currency1 basisFourth quarter diluted earnings per share were $2.01; adjusted1 diluted earnings per share were $2.20Full-year net sales of $7.394 billion increased 6.5% and 7.5% on a constant currency1 basisFull-year diluted earnings per share were $4.88; adjusted1 diluted earnings per share were $7.55Company provides full-year 2024 financial guidanceWARSAW, Ind., Feb. 8, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2023. The Company reported fourth quarter net sales of $1.940 billion, an increase of 6.3% over
WARSAW, Ind., Jan. 16, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 8, 2024 at 8:30 a.m. ET. A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET. The live audio webcast can be accessed via Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. It will be available for replay following the conference call. Individuals in the U.S. and Canada who wish to dial into the conference call may do
WARSAW, Ind., Dec. 14, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2023. The cash dividend of $0.24 per share is payable on or about January 31, 2024 to stockholders of record as of the close of business on December 27, 2023. About the Company Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We